Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist and has published over 200 papers in peer-reviewed journals over the course of her 40-year career, based mainly at Oxford University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.

View Susan’s LinkedIn Page

Craig is a British Scientist, Engineer & Business Leader based in Arizona, USA. He has advised and built accelerated Clinical Trial Platforms (Pfizer & FDA). Craig also has a wealth of Exec and board experience in UK and US start-ups and US Public Companies. Throughout this, he has achieved substantial exits through M&A and IPO’s (NASDAQ). In addition to this, Craig is a Board Member of XPRIZE Foundation.

View Craig’s LinkedIn page

Mike holds a PhD in orthopaedic biotech at the University of Nottingham. He is a Venture Capitalist at a Life Sciences Specialist, . Mike also has a London based Family Office as well as being the CEO of a pre-clinical UK-based biotechnology company: MICA Biosystems

View Michal’s LinkedIn page

Dave is the former chairman and CEO of Office Depot and former president of Sherwin-Williams Paint Stores. In addition to his role as Chairman Emeritus of SSA & Company, he is a Senior Advisor at Peter J. Solomon Company. He formerly served on the boards of Office Depot, Ryder Transportation, Dicks Sporting Good and others. Dave was appointed on the board by Kairos Ventures as an Investor Director for Neuro-Bio.

Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5
years and as CEO of Citigroup’s $10 Billion Global Wealth Management division for 2.5 years. Todd is a
leading practitioner on M&A and business strategy, having led the acquisition and strategy efforts for
Citigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz
Allen Hamilton, and Barents Group.

At Kairos, Todd oversees all operational and financial aspects of the firm and serves on the Kairos
Investment Committee. Kairos has partnered closely with 16 prominent universities to select and
commercialize their most ground-breaking patented innovations in life sciences and physical sciences.

Todd received his MBA, with Distinction, from the Wharton School of Business and his BA in Economics
from Davidson College.

View Todd’s LinkedIn page

James is the founder and Chief Executive of Dragon Argent (formerly Clink Ltd), which provides integrated legal, financial, HR and other professional services to hundreds of tech startups and SME’s, often internationally. James advises a large number of these high growth, entrepreneurial businesses at board level. Having set up his first successful business at 14 (buying and selling old red telephone kiosks), he is a widely experienced entrepreneur and consummate professional, whose passion, integrity and assistance have always been critical to any organisation with which he has been involved.

View James’s LinkedIn page

Professor Paul Herrling was Head of Corporate Research at Novartis. He is also Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore, an endeavour to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding. Prior to this, Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC), he is a member of the Board of the Genomics Institute of the Novartis Research Foundation in La Jolla California and he serves on the boards of several other research institutions. Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA).

View Paul’s LinkedIn page